Adaptive Biotechnologies director Robert Hershberg sells $748k in shares

Director Robert Hershberg of Adaptive Biotechnologies Corp (NASDAQ: ADPT) sold 30,664 shares on August 18, 2026, totalling $748,208 in a series of two transactions. The shares were sold at weighted average prices of $24.39 and $24.41, respectively, with individual sale prices ranging from $24.38 to $24.44. This sale comes amid ADPT's stock trading near its 52-week high of $26.16, following a substantial 107% return over the past year.

Despite this, the stock appears overvalued according to InvestingPro analysis. Prior to these sales, Hershberg had acquired 15,000 shares through stock option exercise at $6.32 per share, totaling $94,800. Post-transaction, he holds 46,683 shares of the company's common stock. Meanwhile, Adaptive Biotechnologies reported a mixed second-quarter performance, with a loss of $0.25 per share missing estimates and revenue of $71.6 million, up 22% from the previous year.

The company's core business and clonoSEQ MRD test franchise showed robust growth. Analysts BTIG and Guggenheim have raised their price targets to $25, citing strong performance in key areas.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.